ETO interacting proteins
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
The 8;21 translocation produces a fusion between the ETO gene and that encoding the myeloid transcription factor AML1. The AML1-ETO fusion substitutes the majority of the ETO protein for the coregulator recruitment domains of AML1. Biochemical analyses of ETO have led to the identification of numerous interacting proteins including many corepressors. Importantly, the proteins interacting with ETO are different from those of wild-type AML1, suggesting that altered coregulator recruitment underlies the oncogenic properties of AML1-ETO. The list of corepressors capable of binding ETO includes histone deacetylases (HDACs) and components of distinct HDAC core complexes. These investigations have provided mechanistic insight into corepressor recruitment by ETO and clues to the leukemogenic activity of AML1-ETO.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but their selectivity profiles extended well beyond these isoforms as reported previously (12, 13, 26, 29, 30, 38).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [13]
Citations
Cites
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230 · cited 1×
“For example, NCoR and SMRT are capable of interacting with Sin3, and this interaction could be facilitated by ETO (Li et al., 1997; Nagy et al., 1997; Soderstrom et al., 1997).”
BackgroundZhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103 · cited 4×
“Purification of the Sin3 complex identified the cooperating components as HDAC1, HDAC2, Sin3-associated proteins 18 and 30 (SAP 18 and 30), and Rb-associated proteins 46 and 48 (RbAp46 and 48) (Zhang et al., 1997, 1998, 1999).”
BackgroundInfluentialXue, Y., Wong, J., Moreno, G. T., Young, M. K., Côté, J., & Wang, W. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80299-3 · Cited by 985 · cited 1×
“HDACs are the enzymatic components of multiprotein complexes such as the N-CoR, SMRT, and Sin3 complexes (Zhang et al., 1997, 1999, 2002; Xue et al., 1998; Guenther et al., 2000; Li et al., 2000; Wen et al., 2000; You et al., 2001; Humphrey et al., 2001; Yoon et al., 2003).”
BackgroundUbiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation
Brooks, C. L., & Gu, W. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00003-6 · Cited by 742 · cited 1×
“Additionally, HDACs can act upon other transcription factors to control DNA binding, nuclear localization, or transcriptional activity (Hung et al., 1999, 2001; Brooks and Gu, 2003).”
BackgroundBoth corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3
Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J. M., Qin, J., & Wong, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4342 · Cited by 629 · cited 5×
“…for example, the functional dependence of ETO on HDAC3 would likely require a direct or indirect association with N-CoR or SMRT, because these proteins are essential for HDAC3’s histone deacetylase activity (Guenther et al., Oncogene 2000; Li et al., 2000; Zhang et al., 2002; Yoon et al., 2003).”
BackgroundInfluentialThe SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3
Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611 · cited 1×
“HDAC3 is the putative enzymatic subunit of the complex and N-CoR or SMRT functions as an essential activating cofactor (Guenther et al., 2001).”
BackgroundSelf-citationHistone Deacetylases and SAP18, a Novel Polypeptide, Are Components of a Human Sin3 Complex
Zhang, Y., Iratni, R., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (1997) · Cell · doi:10.1016/s0092-8674(00)80216-0 · Cited by 578 · cited 4×
“Purification of the Sin3 complex identified the cooperating components as HDAC1, HDAC2, Sin3-associated proteins 18 and 30 (SAP 18 and 30), and Rb-associated proteins 46 and 48 (RbAp46 and 48) (Zhang et al., 1997, 1998, 1999).”
BackgroundInfluentialWang, J., Hoshino, T., Redner, R. L., Kajigaya, S., & Liu, J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10860 · Cited by 512 · cited 8×
“Domains that disrupt interactions between ETO and HDAC complexes also disrupt ETO-mediated repression, consistent with HDACs being critical effectors of ETO (Gelmetti et al., 1998; Lutterbach et al., 1998b; Wang et al., 1998; Hildebrand et al., 2001).”
BackgroundMethodInfluentialCoREST is an integral component of the CoREST- human histone deacetylase complex
You, A., Tong, J. K., Grozinger, C. M., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1454 · Cited by 502 · cited 1×
“HDACs are the enzymatic components of multiprotein complexes such as the N-CoR, SMRT, and Sin3 complexes (Zhang et al., 1997, 1999, 2002; Xue et al., 1998; Guenther et al., 2000; Li et al., 2000; Wen et al., 2000; You et al., 2001; Humphrey et al., 2001; Yoon et al., 2003).”
BackgroundMiyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., & Ohki, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05933.x · Cited by 498 · cited 3×
“Indeed, the protein’s name is an acronym for the translocation (Eight Twenty-One) (Miyoshi et al., 1993).”
Background
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Li, Y., & Seto, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026831 · Cited by 1,284
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429
Lamprecht, B., Walter, K., Kreher, S., Kumar, R., Hummel, M., Lenze, D., Köchert, K., Bouhlel, M. A., Richter, J., Soler, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2129 · Cited by 376
“Although we observed no obvious alteration in the protein expression of the corepressors of N-CoR, SIN3A and SIN3B, the histone deacetylases HDAC1, HDAC2 and HDAC3, the lymphoid-specific helicase or the DNA methyltransferases DNMT1 and DNMT3 (data not shown), we identified an HRS cell–specific loss of the ETO family m…”
BackgroundE Protein Silencing by the Leukemogenic AML1-ETO Fusion Protein
Zhang, J., Kalkum, M., Yamamura, S., Chait, B. T., & Roeder, R. G. (2004) · Science · doi:10.1126/science.1097937 · Cited by 213
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Neganova, M. E., Klochkov, S. G., Aleksandrova, Y. R., & Aliev, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.015 · Cited by 197
Schuh, A. H., Tipping, A. J., Clark, A. J., Hamlett, I., Guyot, B., Iborra, F. J., Rodriguez, P., Strouboulis, J., Enver, T., Vyas, P., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10235-10250.2005 · Cited by 147
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity
Liu, Y., Cheney, M. D., Gaudet, J., Chruszcz, M., Lukasik, S. M., Sugiyama, D., Lary, J. W., Cole, J. L., Dauter, Z., Minor, W., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.012 · Cited by 155
“E: Cos7 cells were cotransfected with HA-tagged (AML1/ETO [A/E] and m7) or nontagged (DNHR2, m4, NHR3x, NHR2x, NHR2x m7, NHR2x m2) AML1/ETO proteins and FLAG-tagged HDAC1, HDAC2, HDAC3, N-CoR, SMRT, PKA RIIa, or HEB.”
InfluentialCdk1 and Cdk2 complexes (cyclin dependent kinases) in apoptosis: a role beyond the cell cycle
Golsteyn, R. M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.08.005 · Cited by 134
Addiction of t(8;21) and inv(16) Acute Myeloid Leukemia to Native RUNX1
Ben-Ami, O., Friedman, D., Leshkowitz, D., Goldenberg, D., Orlovsky, K., Pencovich, N., Lotem, J., Tanay, A., & Groner, Y. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.020 · Cited by 132
Bots, M., Verbrugge, I., Martin, B. P., Salmon, J. M., Ghisi, M., Baker, A., Stanley, K., Shortt, J., Ossenkoppele, G. J., Zuber, J., et al. (2014) · Blood · doi:10.1182/blood-2013-03-488114 · Cited by 133
Liu, Y., Chen, W., Gaudet, J., Cheney, M. D., Roudaia, L., Cierpicki, T., Klet, R. C., Hartman, K. L., Laue, T. M., Speck, N. A., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.010 · Cited by 135
“It interacts with many other proteins including CBFb, SMRT/N-CoR, PLZF, GFI-1, SIN3, and numerous histone deacetylases (Hug and Lazar, 2004).”
BackgroundZaidi, S. K., Dowdy, C. R., van Wijnen, A. J., Lian, J. B., Raza, A., Stein, J. L., Croce, C. M., & Stein, G. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1567 · Cited by 115
Reikvam, H., Hatfield, K. J., Kittang, A. O., Hovland, R., & Bruserud, Ø. (2011) · BioMed Research International · doi:10.1155/2011/104631 · Cited by 112
“The ETO/RUNX1T1-encoded protein referred to as CBFA2T is also a nuclear protein and functions as a transcriptional repressor through its binding to both histone deacetylases and transcription factors [60, 61].”
BackgroundEpigenetics in Cancer: A Hematological Perspective
Stahl, M. F., Kohrman, N., Gore, S. D., Kim, T. K., Zeidan, A. M., & Prébet, T. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006193 · Cited by 99
Kotian, S., Zhang, L., Boufraqech, M., Gaskins, K., Gara, S. K., Quezado, M., Nilubol, N., & Kebebew, E. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1043 · Cited by 88
“It functions as part of the NCoR/SMRT complex along with HDAC1 and HDAC3 to repress the transcriptional activity of cell-cycle checkpoint regulators and differentiation genes (40, 41).”
BackgroundWu, W., Morrissey, C. S., Keller, C. A., Mishra, T., Pimkin, M., Blobel, G. A., Weiss, M. J., & Hardison, R. C. (2014) · Genome Research · doi:10.1101/gr.164830.113 · Cited by 85
“Consider the gene Cbfa2t3, encoding the protein CBFA2T3 (also known as ETO2, MTG16, and MTGR2), a co-repressor (Hug and Lazar 2004) implicated in hematopoietic regulation (Schuh et al. 2005).”
BackgroundVassen, L., Okayama, T., & Möröy, T. (2007) · Blood · doi:10.1182/blood-2006-06-030031 · Cited by 81
NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma
Mattarollo, S. R., West, A. C., Steegh, K., Duret, H., Paget, C., Martin, B. P., Matthews, G. M., Shortt, J., Chesi, M., Bergsagel, P. L., et al. (2012) · Blood · doi:10.1182/blood-2012-04-426643 · Cited by 79
Nuclear receptor corepressor complexes in cancer: mechanism, function and regulation.
Wong, M., Guo, C. H., & Zhang, J. (2014) · PubMed Central · Cited by 104
Genetic manipulation of AML1-ETO–induced expansion of hematopoietic precursors in a Drosophila model
Sinenko, S. A., Hung, T., Moroz, T. P., Tran, Q.-M., Sidhu, S., Cheney, M. D., Speck, N. A., & Banerjee, U. K. (2010) · Blood · doi:10.1182/blood-2010-03-276998 · Cited by 85
Spirin, P., Lebedev, T. D., Orlova, N. N., Горностаева, А. С., Prokofjeva, M. M., Nikitenko, N. A., Dmitriev, S. E., Buzdin, A. A., Borisov, N., Aliper, A. M., et al. (2014) · Leukemia · doi:10.1038/leu.2014.130 · Cited by 74
Co-repressor CBFA2T2 regulates pluripotency and germline development
Tu, S., Narendra, V. K., Yamaji, M., Vidal, S. E., Rojas, L. A., Wang, X., Kim, S. Y., Garcia, B. A., Tuschl, T., Stadtfeld, M., et al. (2016) · Nature · doi:10.1038/nature18004 · Cited by 78
Characterization of Histone Deacetylase Mechanisms in Cancer Development
Hai, R., He, L., Shu, G., & Yin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700947 · Cited by 82
“Furthermore, some HDAC families serve as subunits of large protein complexes and can promote carcinogenesis (76, 77).”
BackgroundChromatin modifying activity of leukaemia associated fusion proteins
Di Croce, L. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi109 · Cited by 68
CBFβ is critical for AML1-ETO and TEL-AML1 activity
Roudaia, L., Cheney, M. D., Manuylova, E., Chen, W., Morrow, M., Park, S., Lee, C.-T., Kaur, P., Williams, O., Bushweller, J. H., et al. (2009) · Blood · doi:10.1182/blood-2008-03-147207 · Cited by 59
Kumar, R., Manning, J. A., Spendlove, H. E., Kremmidiotis, G., McKirdy, R., Lee, J., Millband, D. N., Cheney, K. M., Stampfer, M. R., Dwivedi, P. P., et al. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0249 · Cited by 57
“ETO proteins have been shown to localize to the nucleus, function as transcriptional repressors, and can homodimerize and heterodimerize to generate a diversity of repressor complexes (30, 31).”
BackgroundDimer-tetramer transition controls RUNX1/ETO leukemogenic activity
Wichmann, C. W., Becker, Y., Chen-Wichmann, L., Vogel, V., Vojtkova, A., Herglotz, J., Moore, S., Koch, J., Lausen, J., Mäntele, W., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248047 · Cited by 55
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 63
“However, the contribution of HDAC to AML pathogenesis has been linked to aberrant recruitment of these enzymes by myeloid oncoproteins such as AML1-ETO, PML-RARA, and EVI1 (Izutsu et al., 2001; Senyuk et al., 2002; Hug and Lazar, 2004; Falkenberg and Johnstone, 2014).”
BackgroundSalat, D., Liefke, R., Wiedenmann, J., Borggrefe, T., & Oswald, F. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01966-07 · Cited by 54
The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor
Wildonger, J., & Mann, R. S. (2005) · Development · doi:10.1242/dev.01824 · Cited by 54
“The Drosophila eye has also been used to analyze other human disease genes, including those that contribute to neurodegeneration such as spinocerebellar ataxia and huntingtin (Jackson et al., 1998; Kazantsev et al., 2002) (reviewed by Bonini and Fortini, 2002).”
CBFA2T3-ZNF652 Corepressor Complex Regulates Transcription of the E-box Gene HEB
Kumar, R., Cheney, K. M., McKirdy, R., Neilsen, P. M., Schulz, R. B., Lee, J., Cohen, J., Booker, G. W., & Callen, D. F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709136200 · Cited by 48
Kwok, C., Zeisig, B. B., Qiu, J. J., Dong, S., & So, C. W. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810558106 · Cited by 51
“However, in addition to homooligomerization, NHR2 is also responsible for hetero-oligomeric interaction with various proteins in the complexes (9, 13).”
BackgroundInfluentialRoles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
Zhang, J., Gao, X., & Yu, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741746 · Cited by 50
Post-translational modifications of Runx1 regulate its activity in the cell
Wang, L., Huang, G., Zhao, X., Hatlen, M. A., Vu, L., Liu, F., & Nimer, S. D. (2009) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2009.03.005 · Cited by 50
“N-CoR, typically complexed with SMRT, can bind ETO at the NHR4 site and also bind HDAC3[48].”
BackgroundHistone Deacetylase Inhibitors and Rational Combination Therapies
Grant, S., & Dai, Y. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394387-3.00006-9 · Cited by 50
Kulka, L. A. M., Fangmann, P.-V., Panfilova, D., & Olzscha, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00425 · Cited by 44
Plevin, M. J., Zhang, J., Guo, C. H., Roeder, R. G., & Ikura, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603463103 · Cited by 40
Structure of the AML1-ETO eTAFH domain–HEB peptide complex and its contribution to AML1-ETO activity
Park, S., Chen, W., Cierpicki, T., Tonelli, M., Cai, X., Speck, N. A., & Bushweller, J. H. (2009) · Blood · doi:10.1182/blood-2008-06-161307 · Cited by 42
Jin, W., Wu, K., Yz, L., Yang, W.-T., Zou, B., Zhang, F., Zhang, J., & Wang, K.-K. (2012) · Oncogene · doi:10.1038/onc.2012.204 · Cited by 36
Differential Roles for the E2A Activation Domains in B Lymphocytes and Macrophages
Bhalla, S., Spaulding, C., Brumbaugh, R. L., Zagort, D. E., Massari, M. E., Murre, C., & Kee, B. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1694 · Cited by 33
Proline Rich Motifs as Drug Targets in Immune Mediated Disorders
Srinivasan, M., & Dunker, A. K. (2012) · International Journal of Peptides · doi:10.1155/2012/634769 · Cited by 36
“Interestingly, a peptide derived from the SMRT-RD3 has been shown to specifically bind the MYND domain of AML/ETO.”
BackgroundInfluentialELA2 is regulated by hematopoietic transcription factors, but not repressed by AML1-ETO
Lausen, J., Liu, S., Fliegauf, M., Lübbert, M., & Werner, M. H. (2005) · Oncogene · doi:10.1038/sj.onc.1209181 · Cited by 34
“To explore this view of AML1-ETO further, the biochemical and structural basis for the interaction between AML1-ETO and its binding partners needs to explored (reviewed in Hug and Lazar, 2004).”
BackgroundEngel, M. E., Nguyen, H. N., Mariotti, J., Hunt, A. A., & Hiebert, S. W. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01342-09 · Cited by 31
“MTG16 concentrates in the nucleus, binds multiple nuclear proteins that regulate gene expression, and can repress gene expression when tethered to promoters by DNA binding domains of transcriptional regulators (11, 22) (see Fig.”
BackgroundGuo, X., Plank-Bazinet, J. L., Krivega, I. V., Dale, R., & Dean, A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa736 · Cited by 32
Guo, C. H., Hu, Q., Yan, C., & Zhang, J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00073-09 · Cited by 33
“The eight-twenty-one gene product ETO (also called MTG8) is a prototypical member of a small family of transcriptional corepressors that also includes ETO-2 and MTGR1 (MTG8-related protein 1) (29).”
BackgroundResultInfluentialLausen, J., Cho, S., Liu, S., & Werner, M. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407239200 · Cited by 34
Spirin, P., Lebedev, T. D., Orlova, N., Morozov, A. V., Poymenova, N., Dmitriev, S. E., Buzdin, A. A., Stocking, C., Kovalchuk, O., & Prassolov, V. (2017) · Oncotarget · doi:10.18632/oncotarget.18503 · Cited by 29
Histone deacetylase (HDACs) inhibitors: Clinical applications
Shanmukha, K. D., Paluvai, H., Lomada, S. K., Gokara, M., & Kalangi, S. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.02.011 · Cited by 29
Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi-1 leukemia cells
Zhang, Z., Hao, C.-L., Liu, P., TIAN, X., Wang, L., Zhao, L., & Zhu, C. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1834 · Cited by 25
Steinauer, N., Guo, C. H., Huang, C., Wong, M., Tu, Y., Freter, C. E., & Zhang, J. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028514 · Cited by 28
RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia
van der Kouwe, E., & Staber, P. B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020350 · Cited by 29
“Yeast two-hybrid and chromatin immunoprecipitation assays revealed the importance of NHR2 and NHR4 domains in the interactions of ETO and RUNX1-ETO with HDAC1, HDAC2, and HDAC3 [70,77,133,134].”
BackgroundDifferential involvement of E2A-corepressor interactions in distinct leukemogenic pathways
Gow, C., Guo, C. H., Wang, D., Hu, Q., & Zhang, J. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt855 · Cited by 24
Off to a Bad Start: Cancer Initiation by Pluripotency Regulator PRDM14
Tracey, L. J., & Justice, M. J. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.04.004 · Cited by 24
“Each of the three ETO/CBFA2T family members participates in oncogenic translocations with RUNX1 in AML[47, 48].”
BackgroundRulina, A. V., Spirin, P., & Prassolov, V. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910130092 · Cited by 25
Zhang, Q., Wang, P., Hou, H., Zhang, H., Tan, J., Huang, Y., Li, Y., Wu, J., Qiu, Z., & Li, L. (2016) · PROTOPLASMA · doi:10.1007/s00709-015-0928-9 · Cited by 22
Structure of the AML1-ETO NHR3–PKA(RIIα) Complex and Its Contribution to AML1-ETO Activity
Corpora, T., Roudaia, L., Oo, Z. M., Chen, W., Manuylova, E., Cai, X., Chen, M. J., Cierpicki, T., Speck, N. A., & Bushweller, J. H. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.08.007 · Cited by 24
Identification of RUNX1T1 as a potential epigenetic modifier in small‐cell lung cancer
He, T., Wildey, G. M., McColl, K. S., Savadelis, A., Spainhower, K. B., McColl, C., Kresak, A. M., Tan, A. C., Yang, M., Abbas, A., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12829 · Cited by 23
Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors
Hao, C.-L., Liu, P., Zhao, L., Zhu, C., Tian, X., Wang, L., & Zhang, Z. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s46135 · Cited by 20
Molecular pathways driven by ETO2-GLIS2 in aggressive pediatric leukemia
Thirant, C., Lopez, C. K., Malinge, S., & Mercher, T. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1345351 · Cited by 19
“ETO proteins are generally associated with transcriptional repression through the recruitment of nuclear corepressors such as the SIN3 transcription regulator family member A (SIN3A) or the Nuclear receptor co-repressors (NCOR), or numerous histones deacetylases (HDAC).(2) GLIS2 is a member of the GLI- family of trans…”
BackgroundFeedback regulation of NEUROG2 activity by MTGR1 is required for progression of neurogenesis
Aaker, J., Patineau, A. L., Yang, H.-J., Ewart, D. T., Gong, W., Li, T., Nakagawa, Y., McLoon, S. C., & Koyano‐Nakagawa, N. (2009) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.07.011 · Cited by 21
Repeat element-driven activation of proto-oncogenes in human malignancies
Lamprecht, B., Bonifer, C., & Mathas, S. (2010) · Cell Cycle · doi:10.4161/cc.9.21.13682 · Cited by 21
Regulation of V(D)J Recombination by E-Protein Transcription Factors
Jones, M. E., & Zhuang, Y. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-0296-2_12 · Cited by 18
RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1
Ponnusamy, K., Kohrs, N., Ptasinska, A., Assi, S. A., Herold, T., Hiddemann, W., Lausen, J., Bonifer, C., Henschler, R., & Wichmann, C. W. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.6 · Cited by 20
A neurogenetic mechanism of experience-dependent suppression of aggression
Ishii, K., Cortese, M., Leng, X., Shokhirev, M. N., & Asahina, K. (2022) · Science Advances · doi:10.1126/sciadv.abg3203 · Cited by 16
“Biochemical and genetic data suggest that MTGs are involved in cellular differentiation and organ development by serving as a scaffold protein for a transcription regulatory complex that mainly represses gene expression ( 75 , 76 , 79 , 80 , 86 , 87 ).”
LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML
Chen, Q., Cevher, M. A., Jiang, Q., Wang, S., Sun, X., Roeder, R. G., & Chen, M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213718119 · Cited by 17
Zhou, J., Xie, H., Liu, Z., Luo, H., & Wu, R. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500513n · Cited by 18
Guo, C. H., Li, J., Steinauer, N., Wong, M., Wu, B., Dickson, A. M., Kalkum, M., & Zhang, J. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010707 · Cited by 16
“NHR1 is also engaged in interactions with the p300 histone acetyltransferase (6) whereas NHR2 is engaged in oligomerization (2).”
BackgroundEpigenetic mechanisms in leukemia
Zaidi, S. K., Trombly, D. J., Dowdy, C. R., Lian, J. B., Stein, J. L., van Wijnen, A. J., & Stein, G. S. (2012) · Advances in Biological Regulation · doi:10.1016/j.jbior.2012.05.001 · Cited by 16
CBFA2T3–ZNF651, like CBFA2T3–ZNF652, functions as a transcriptional corepressor complex
Kumar, R., Cheney, K. M., Neilsen, P. M., Schulz, R. B., & Callen, D. F. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.047 · Cited by 15
“ETOs are scaffold proteins that recruit a range of corepressor proteins such as N-CoR, SMRT, Sin3A and ATN1 and HDACs to generate complexes that function to repress gene transcription [3].”
BackgroundInteraction of MTG family proteins with NEUROG2 and ASCL1 in the developing nervous system
Aaker, J., Patineau, A. L., Yang, H.-J., Ewart, D. T., Nakagawa, Y., McLoon, S. C., & Koyano‐Nakagawa, N. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.004 · Cited by 15
Sawney, S., Arora, R., Aggarwal, K. K., & Saluja, D. (2015) · Journal of Oncology · doi:10.1155/2015/781473 · Cited by 14
“The ETO protein, a corepressor, is characterized by its four conservedNervyHomologyRegions (NHR1 to NHR4) that play an important role in proteinprotein interactions [9].”
BackgroundTracey, L. J., Brooke-Bisschop, T., Jansen, P. W. T. C., Campos, E. I., Vermeulen, M., & Justice, M. J. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1327 · Cited by 13
Chromosomal aberrations and fusion genes in myeloid malignancies
Gianfelici, V., Lahortiga, I., & Cools, J. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.30 · Cited by 14
Proleukemic RUNX1 and CBFβ Mutations in the Pathogenesis of Acute Leukemia
Engel, M. E., & Hiebert, S. W. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-69259-3_8 · Cited by 14
Steinauer, N., Zhang, K., Guo, C. H., & Zhang, J. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3078128 · Cited by 12
“For example, AML1-ETO-p300 interaction is thought to allow AML1-ETO to activate transcription [14], and AML1-ETO-NCoR/SMRT/HDAC interaction is thought to allow AML1-ETO to repress transcription [15], [16].”
BackgroundDecoding of exon splicing patterns in the human RUNX1–RUNX1T1 fusion gene
Grinev, V. V., Migas, A. A., Kirsanava, A. D., Mishkova, V., Siomava, N., Ramanouskaya, T. V., Vaitsiankova, A., Ilyushonak, I. M., Nazarov, P. V., Vallar, L., et al. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.08.017 · Cited by 18
Kellaway, S. G., Chin, P. S., Barneh, F., Bonifer, C., & Heidenreich, O. T. (2020) · Cells · doi:10.3390/cells9122681 · Cited by 11
“NHR4 recruits, SMRT (Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptors) and SIN3, class I HDACs via nuclear receptor corepressor (NCOR) [11].”
BackgroundInfluentialStructure and Biophysics of CBFβ/RUNX and Its Translocation Products
Tahirov, T. H., & Bushweller, J. H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_2 · Cited by 12
Wu, L., Huang, J. L., Trivedi, P., Sun, X., Yu, H., He, Z., & Zhang, X. (2022) · Discover Oncology · doi:10.1007/s12672-022-00597-9 · Cited by 11
“mSin3a, and histone deacetylases (HDACs) [26, 84].”
Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO
Hines, R., Boyapati, A., & Zhang, D. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.05.005 · Cited by 10
“Instead, ETO contains regions highly homologous to the Drosophila Nervy protein and has been found to interact with transcription factors and negative regulators of transcription [3;44;55].”
BackgroundTargeting Cancer at the Intersection of Signaling and Epigenetics
Guerra, S. L., & Cichowski, K. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050400 · Cited by 7
“Studies exploring mechanisms of resistance to BET inhibitors have also revealed cooperativity between Wnt signaling pathways in AML.”
BackgroundInfluentialRegional expression of MTG genes in the developing mouse central nervous system
Alishahi, A., Koyano‐Nakagawa, N., & Nakagawa, Y. (2009) · Developmental Dynamics · doi:10.1002/dvdy.22021 · Cited by 11
Activated leukemic oncogenes responsible for neoplastic transformation of hematopoietic cells
Baskaran, D., Spirin, P., & Prassolov, V. (2010) · Molecular Biology · doi:10.1134/s0026893310030039 · Cited by 6
“Many putative mechanisms are known for the effects of the transcriptional repressors and corepressors that recruit HDACs [ 36 ].”
BackgroundInfluentialFukunaga, J.-I., Nomura, Y., Tanaka, Y., Torigoe, H., Nakamura, Y., Sakamoto, T., & Kozu, T. (2020) · FEBS Letters · doi:10.1002/1873-3468.13914 · Cited by 6
Garfinkle, E. A. R., Nallagatla, P., Sahoo, B. K., Dang, J., Balood, M., Cotton, A., Franke, C., Mitchell, S., Wilson, T. L., & Gruber, T. A. (2024) · Nature Communications · doi:10.1038/s41467-024-53158-9 · Cited by 6
“NHR2 contains a hydrophobic heptad repeat region that plays a key role in homo-and hetero-oligomerization with the closely related transcriptional repressor ETO (also known as RUNX1T1 and CBFA2T1) 30 .”
Saikia, S., Pal, U., Kalita, D. J., Kumar, A., Sarma, A., Kataki, A. C., & Limaye, A. M. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06542-3 · Cited by 5
Imai, K., & Taniguchi, H. (2022) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.98.017 · Cited by 4
Nanocolonies and diagnostics of oncological diseases associated with chromosomal translocations
Chetverina, Е. V., & Chetverin, A. B. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910130109 · Cited by 4
In VivoChemical Screening for Modulators of Hematopoiesis and Hematological Diseases
Zhang, Y., & Yeh, J.-R. J. (2012) · Advances in Hematology · doi:10.1155/2012/851674 · Cited by 3
“HDAC is a transcription corepressor that is known to interact with the ETO moiety of the AML1-ETO protein [123].”
BackgroundChen, Y., Liu, E., Ding, X., Qin, C., Jiang, Y., & Li, X. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109520 · Cited by 3
Epigenetic Modifications Mediated by the AML1/ETO and MLL Leukemia Fusion Proteins
Duque‐Afonso, J., Lübbert, M., & Cleary, M. L. (2013) · Springer eBooks · doi:10.1007/978-3-642-38404-2_6 · Cited by 2
Structural Allostery and Protein–Protein Interactions of Sin3
Hasan, T., & Saluja, D. (2015) · Springer eBooks · doi:10.1007/978-81-322-2467-9_1 · Cited by 2
Structural basis of multimer-mediated mayhem
Sitwala, K. V., & Hess, J. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.022 · Cited by 1
Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects
Tedjaseputra, A., Galli, S., Ibrahim, M., Harrison, C. N., & McLornan, D. P. (2016) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1149467 · Cited by 1
Ni, Y., Shi, M., Lin, D., Lin, Y., Xue, H., Dong, X., Liu, L., Sar, F., Wu, R., Morova, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.14.653660 · Cited by 1
“In this fusion gene, RUNX1T1 (ETO) serves as an inhibitory platform for different HDAC family members to form repressive complex and suppresses AML1-regulating downstream genes via deacetylation, thus promoting carcinogenesis [29, 30] .”
The function of TCF4 in Pitt-Hopkins syndrome and schizophrenia
Forrest, M. P. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Epigenetics in Pediatric Cancers
Ciarapica, R., Raimondi, L., Verginelli, F., & Rota, R. (2011) · Wiley eBooks · doi:10.1002/9781118005743.ch9 · Cited by 1
Role of E-proteins in B Lymphocyte Commitment and Thymocyte Selection
Jones, M. E. (2009) · DukeSpace (Duke University)
Hiebert, S. W., Engel, M. E., Nguyen, H. N., & Mariotti, J. (2014)
Metadata
- Authors
- Hug, B. A., & Lazar, M. A.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Hug, Bruce A
- Lazar, Mitchell A
- Venue
- Oncogene
- Published
- 2004-05-24
- Volume
- 23
- Issue
- 24
- Pages
- 4270-4274
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2020677165
- Cited by
- 112
- References
- 47
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 5 · 2020: 7 · 2019: 6 · 2018: 1 · 2017: 4 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 7 · 2012: 8
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08hl004339-03)
- National Heart, Lung, and Blood Institute (HL004339)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK43806, R01DK045586, DK 45586)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- ETO, AML1-ETO fusion, 21 translocation, corepressors, coregulator recruitment, histone deacetylase, protein-protein interaction, leukemogenesis
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, DNA-Binding Proteins, Histone Deacetylases, Humans, Nuclear Proteins, Repressor Proteins, Transcription Factors, Oncogene Proteins, Fusion, Protein Structure, Tertiary, Core Binding Factor Alpha 2 Subunit, Sin3 Histone Deacetylase and Corepressor Complex, Nuclear Receptor Co-Repressor 1, Nuclear Receptor Co-Repressor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.